vs
Side-by-side financial comparison of BV Financial, Inc. (BVFL) and Protalix BioTherapeutics, Inc. (PLX). Click either name above to swap in a different company.
BV Financial, Inc. is the larger business by last-quarter revenue ($10.5M vs $9.1M, roughly 1.2× Protalix BioTherapeutics, Inc.). BV Financial, Inc. runs the higher net margin — 45.6% vs -60.3%, a 105.9% gap on every dollar of revenue. On growth, BV Financial, Inc. posted the faster year-over-year revenue change (9.2% vs -49.9%). BV Financial, Inc. produced more free cash flow last quarter ($18.8M vs $1.6M). Over the past eight quarters, BV Financial, Inc.'s revenue compounded faster (11.1% CAGR vs -6.7%).
Virtu Financial, Inc. is an American high-frequency trading company. The company went public on the Nasdaq in 2015.
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
BVFL vs PLX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $10.5M | $9.1M |
| Net Profit | $4.8M | $-5.5M |
| Gross Margin | — | 49.4% |
| Operating Margin | 66.9% | -51.1% |
| Net Margin | 45.6% | -60.3% |
| Revenue YoY | 9.2% | -49.9% |
| Net Profit YoY | 146.2% | -184.8% |
| EPS (diluted) | $0.52 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $10.5M | $9.1M | ||
| Q3 25 | $10.0M | $17.9M | ||
| Q2 25 | $9.9M | $15.7M | ||
| Q1 25 | $9.2M | $10.1M | ||
| Q4 24 | $9.7M | $18.2M | ||
| Q3 24 | $10.0M | $18.0M | ||
| Q2 24 | $9.5M | $13.5M | ||
| Q1 24 | $8.5M | — |
| Q4 25 | $4.8M | $-5.5M | ||
| Q3 25 | $3.7M | $2.4M | ||
| Q2 25 | $2.9M | $164.0K | ||
| Q1 25 | $2.1M | $-3.6M | ||
| Q4 24 | $2.0M | $6.5M | ||
| Q3 24 | $3.8M | $3.2M | ||
| Q2 24 | $3.4M | $-2.2M | ||
| Q1 24 | $2.6M | — |
| Q4 25 | — | 49.4% | ||
| Q3 25 | — | 53.4% | ||
| Q2 25 | — | 62.5% | ||
| Q1 25 | — | 19.1% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 53.4% | ||
| Q2 24 | — | 29.8% | ||
| Q1 24 | — | — |
| Q4 25 | 66.9% | -51.1% | ||
| Q3 25 | 51.5% | 11.9% | ||
| Q2 25 | 39.9% | 7.5% | ||
| Q1 25 | 29.4% | -41.0% | ||
| Q4 24 | 29.5% | 39.6% | ||
| Q3 24 | 52.4% | 22.2% | ||
| Q2 24 | 49.6% | -18.0% | ||
| Q1 24 | 42.1% | — |
| Q4 25 | 45.6% | -60.3% | ||
| Q3 25 | 37.2% | 13.2% | ||
| Q2 25 | 29.0% | 1.0% | ||
| Q1 25 | 22.9% | -35.8% | ||
| Q4 24 | 20.2% | 35.6% | ||
| Q3 24 | 38.0% | 18.0% | ||
| Q2 24 | 35.8% | -16.4% | ||
| Q1 24 | 30.1% | — |
| Q4 25 | $0.52 | $-0.06 | ||
| Q3 25 | $0.41 | $0.03 | ||
| Q2 25 | $0.29 | $0.00 | ||
| Q1 25 | $0.21 | $-0.05 | ||
| Q4 24 | $0.18 | $0.10 | ||
| Q3 24 | $0.35 | $0.03 | ||
| Q2 24 | $0.32 | $-0.03 | ||
| Q1 24 | $0.24 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $55.7M | $14.7M |
| Total DebtLower is stronger | $35.0M | — |
| Stockholders' EquityBook value | $183.8M | $48.2M |
| Total Assets | $912.2M | $82.3M |
| Debt / EquityLower = less leverage | 0.19× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $55.7M | $14.7M | ||
| Q3 25 | $63.5M | $13.6M | ||
| Q2 25 | $56.3M | $17.9M | ||
| Q1 25 | $70.8M | $19.5M | ||
| Q4 24 | $70.5M | $19.8M | ||
| Q3 24 | $94.1M | $27.4M | ||
| Q2 24 | $90.6M | $23.4M | ||
| Q1 24 | $78.8M | — |
| Q4 25 | $35.0M | — | ||
| Q3 25 | $35.0M | — | ||
| Q2 25 | $35.0M | — | ||
| Q1 25 | $49.9M | — | ||
| Q4 24 | $49.9M | — | ||
| Q3 24 | $34.8M | — | ||
| Q2 24 | $34.8M | — | ||
| Q1 24 | $34.8M | — |
| Q4 25 | $183.8M | $48.2M | ||
| Q3 25 | $190.2M | $52.9M | ||
| Q2 25 | $198.0M | $49.9M | ||
| Q1 25 | $198.1M | $45.2M | ||
| Q4 24 | $195.5M | $43.2M | ||
| Q3 24 | $209.7M | $32.4M | ||
| Q2 24 | $205.5M | $28.6M | ||
| Q1 24 | $201.8M | — |
| Q4 25 | $912.2M | $82.3M | ||
| Q3 25 | $909.4M | $82.3M | ||
| Q2 25 | $908.3M | $78.5M | ||
| Q1 25 | $921.9M | $73.9M | ||
| Q4 24 | $911.8M | $73.4M | ||
| Q3 24 | $892.7M | $61.6M | ||
| Q2 24 | $897.2M | $91.5M | ||
| Q1 24 | $892.5M | — |
| Q4 25 | 0.19× | — | ||
| Q3 25 | 0.18× | — | ||
| Q2 25 | 0.18× | — | ||
| Q1 25 | 0.25× | — | ||
| Q4 24 | 0.26× | — | ||
| Q3 24 | 0.17× | — | ||
| Q2 24 | 0.17× | — | ||
| Q1 24 | 0.17× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $19.0M | $2.0M |
| Free Cash FlowOCF − Capex | $18.8M | $1.6M |
| FCF MarginFCF / Revenue | 178.2% | 17.8% |
| Capex IntensityCapex / Revenue | 2.2% | 4.4% |
| Cash ConversionOCF / Net Profit | 3.96× | — |
| TTM Free Cash FlowTrailing 4 quarters | $34.0M | $-13.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $19.0M | $2.0M | ||
| Q3 25 | $8.4M | $-3.7M | ||
| Q2 25 | $2.7M | $-5.2M | ||
| Q1 25 | $4.4M | $-5.1M | ||
| Q4 24 | $16.1M | $4.0M | ||
| Q3 24 | $6.1M | $4.1M | ||
| Q2 24 | $1.5M | $-3.6M | ||
| Q1 24 | $4.6M | — |
| Q4 25 | $18.8M | $1.6M | ||
| Q3 25 | $8.4M | $-4.2M | ||
| Q2 25 | $2.6M | $-5.7M | ||
| Q1 25 | $4.2M | $-5.4M | ||
| Q4 24 | $15.5M | $3.6M | ||
| Q3 24 | $6.0M | $4.0M | ||
| Q2 24 | $1.4M | $-3.8M | ||
| Q1 24 | $4.1M | — |
| Q4 25 | 178.2% | 17.8% | ||
| Q3 25 | 84.0% | -23.7% | ||
| Q2 25 | 26.1% | -36.2% | ||
| Q1 25 | 46.0% | -53.0% | ||
| Q4 24 | 160.0% | 19.6% | ||
| Q3 24 | 59.6% | 22.4% | ||
| Q2 24 | 15.2% | -28.1% | ||
| Q1 24 | 48.4% | — |
| Q4 25 | 2.2% | 4.4% | ||
| Q3 25 | 0.1% | 2.8% | ||
| Q2 25 | 1.4% | 2.8% | ||
| Q1 25 | 2.4% | 3.0% | ||
| Q4 24 | 6.3% | 2.3% | ||
| Q3 24 | 1.0% | 0.5% | ||
| Q2 24 | 0.6% | 1.3% | ||
| Q1 24 | 5.1% | — |
| Q4 25 | 3.96× | — | ||
| Q3 25 | 2.26× | -1.58× | ||
| Q2 25 | 0.95× | -31.91× | ||
| Q1 25 | 2.11× | — | ||
| Q4 24 | 8.23× | 0.61× | ||
| Q3 24 | 1.60× | 1.27× | ||
| Q2 24 | 0.44× | — | ||
| Q1 24 | 1.77× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BVFL
Segment breakdown not available.
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
